Gland Pharma Limited has officially informed the stock exchanges regarding the outcome of its Board Meeting held on April 09, 2026. The Board has approved the re-appointment of Ms. Naina Lal Kidwai as an Independent Director for a second consecutive term of five years. This tenure is set to commence on May 17, 2026, and will conclude on May 16, 2031, subject to the necessary approval from company members through a postal ballot and e-voting process.

Ms. Naina Lal Kidwai is a highly distinguished professional, currently serving as the Chairman of Rothschild & Co India and holding advisory roles with Advent Private Equity and TPG Rise Climate. A Harvard Business School MBA graduate and recipient of the Padma Shri, she has authored several books, including “30 Women in Power: Their Voices, Their Stories”. Her extensive board experience includes past leadership as Chairman of HSBC India and executive roles at HSBC Asia Pacific, as well as serving on the global board of Nestle.

Gland Pharma operates primarily as a business-to-business (B2B) generic injectables manufacturer with a presence in over 60 countries. In 2025, the company made significant strides by acquiring Cenexi, a French CDMO, which now contributes approximately 26% of its overall revenue. Recent developments in 2025 also include the approval of its Employee Stock Option Scheme (ESOP 2025) and receiving USFDA approvals for several products, such as Zoledronic Acid Injection and Olopatadine Hydrochloride Ophthalmic Solution.

For the quarter ended December 31, 2025 (Q3 FY26), Gland Pharma reported a consolidated revenue from operations of 16,953.6 Million. The company achieved a net profit of 2,614.8 Million for the same period. These results reflect the company’s ongoing efforts to maintain growth through niche launches and strategic deal wins. Notable institutional investors in the company include Shanghai Fosun Pharmaceutical, which remains the promoter with a 51.83% stake, alongside major entities like HDFC Asset Management and The Vanguard Group.